Recombinant CD59 Monoclonal Antibody (AN301483L)
For research use only.
| Verified Samples |
Verified Samples in WB: HeLa Verified Samples in IHC: Human placenta, Human bladder cancer |
| Dilution | WB 1:500-1:2000, IHC 1:200-1:1000 |
| Isotype | IgG, κ |
| Host | Rabbit |
| Reactivity | Human, |
| Applications | WB, IHC |
| Clonality | Monoclonal;Recombinant |
| Immunogen | Recombinant human CD59 fragment |
| Abbre | CD59 |
| Synonyms | MEM, MIC, MSK, p18, 16.3A, MIC11MSK, HRF, MIN, CD59, 16.3A5, 1F5, EJ16, EJ30, EL32, G344, HRF-20, HRF20, MAC-IP, MACIF, MEM43, MIC11, MIN1, MIN2, MIN3, MIRL, MSK21, p18-20, 1F5 antigen, 20 kDa homologous restriction factor, CD59 antigen, CD59 glycoprotein, FLJ38134, FLJ92039, HRF 20, Ly 6, MIC11MSK21, Protectin, H19, 1F-5Ag, CD 59, CD_antigen=CD59, CD59 antigen complement regulatory protein, CD59 antigen p18 20, CD59 antigen p18-20 (antigen identified by monoclonal antibodies 16.3A5, CD59 molecule, CD59 molecule complement regulatory protein, Cd59a, Complement regulatory protein, EL32 and G344), Human leukocyte antigen MIC11, Ly 6, Ly 6 like protein, Lymphocytic antigen CD59/MEM43, MAC inhibitory protein, MAC IP, MAC-inhibitory protein, MACIP, MEM43 antigen, Membrane attack complex (MAC) inhibition factor, Membrane attack complex inhibition factor, Membrane inhibitor of reactive lysis, MGC2354, p18 20, Surface antigen recognized by monoclonal 16.3A5, T cell activating protein |
| Swissprot | |
| Calculated MW | 14 kDa |
| Observed MW |
18 kDa
The actual band is not consistent with the expectation.
Western blotting is a method for detecting a certain protein in a complex sample based on the specific binding of antigen and antibody. Different proteins can be divided into bands based on different mobility rates. The mobility is affected by many factors, which may cause the observed band size to be inconsistent with the expected size. The common factors include: 1. Post-translational modifications: For example, modifications such as glycosylation, phosphorylation, methylation, and acetylation will increase the molecular weight of the protein. 2. Splicing variants: Different expression patterns of various mRNA splicing bodies may produce proteins of different sizes. 3. Post-translational cleavage: Many proteins are first synthesized into precursor proteins and then cleaved to form active forms, such as COL1A1. 4. Relative charge: the composition of amino acids (the proportion of charged amino acids and uncharged amino acids). 5. Formation of multimers: For example, in protein dimer, strong interactions between proteins can cause the bands to be larger. However, the use of reducing conditions can usually avoid the formation of multimers. If a protein in a sample has different modified forms at the same time, multiple bands may be detected on the membrane. |
| Cellular Localization | Membrane |
| Concentration | 1 mg/mL |
| Buffer | PBS, 50% glycerol, 0.05% Proclin 300, 0.05% protein protectant. |
| Purification Method | Protein A purified |
| Research Areas | Immunology, Signal Transduction, Stem Cells, Cardiovascular |
| Clone No. | A178 |
| Conjugation | Unconjugated |
| Storage | Store at -20°C Valid for 12 months. Avoid freeze / thaw cycles. |
| Shipping | Ice bag |
| background | CD59 is a widely expressed membrane regulatory protein, and its C-terminus is fixed on the cell surface via a GPI anchor. CD59 has different names due to its functions, such as homologous restriction factor-20, protectin and membrane inhibitor of reactive lysis (MIRL). The main physiological function of CD59 is to prevent the complement membrane attack complex (MAC) from lysing and destroying cells of the same species or its own, that is, homologous species restriction (HSR). |
Other Clones
{{antibodyDetailsPage.numTotal}} Results
-
{{item.title}}
Citations ({{item.publications_count}}) Manual MSDS
Cat.No.：{{item.cat}}
{{index}} {{goods_show_value}}
Other Formats
{{formatDetailsPage.numTotal}} Results
Unconjugated
-
{{item.title}}
Citations ({{item.publications_count}}) Manual MSDS
Cat.No.：{{item.cat}}
{{index}} {{goods_show_value}}
-
IF：{{item.impact}}
Journal：{{item.journal}} ({{item.year}})
DOI：{{item.doi}}Reactivity：{{item.species}}
Sample Type：{{item.organization}}
-
Q{{(FAQpage.currentPage - 1)*pageSize+index+1}}:{{item.name}}
